Imbruvica (ibrutinib) / Generic mfg., AbbVie, J&J 
Welcome,         Profile    Billing    Logout  

130 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imbruvica (ibrutinib) / AbbVie, J&J
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Checkmark From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Hourglass Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL
More
Recruiting
1/2
320
US
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Juno Therapeutics, a Subsidiary of Celgene
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
11/27
11/27
CA-4948-101, NCT03328078: A Study of CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Hourglass Apr 2021 - Sep 2021 : Early data from trial in combination with CA-4948 for r/r NHL
Checkmark From dose escalation study in patients with DH/DE DLBCL
Dec 2019 - Dec 2019: From dose escalation study in patients with DH/DE DLBCL
Checkmark Data from r/r NHL, DLBCL, Waldenström's macroglobulinemia and oncogenic MYD88 mutations
Dec 2019 - Dec 2019: Data from r/r NHL, DLBCL, Waldenström's macroglobulinemia and oncogenic MYD88 mutations
More
Recruiting
1/2
80
Europe, US, RoW
Emavusertib, CA-4948, ibrutinib
Curis, Inc.
Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
08/26
08/26
NCT02315326: Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Recruiting
1/2
109
US
Ibrutinib, Imbruvica™, HD- Methotrexate (MTX), Rituximab + HD- Methotrexate (MTX), procarbazine
Memorial Sloan Kettering Cancer Center, Pharmacyclics LLC., Janssen Biotech, Inc.
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
12/26
12/26
CYTB323A12101, NCT03960840: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL

Recruiting
1/2
225
Europe, Japan, US, RoW
Rapcabtagene autoleucel single agent, Ibrutinib
Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
06/27
06/27
CIRLL study, NCT03420183: A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Recruiting
1b
156
US
Cirmtuzumab followed by Cirmtuzumab plus ibrutinib, UC-961, Imbruvica, Cirmtuzumab plus ibrutinib, Ibrutinib
Oncternal Therapeutics, Inc, University of California, San Diego, California Institute for Regenerative Medicine (CIRM)
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma
04/19
12/22
NCT01479842: Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Checkmark In pts with previously untreated & relapsed/refractory NHL
Oct 2014 - Oct 2014: In pts with previously untreated & relapsed/refractory NHL
Active, not recruiting
1
48
US
BTK inhibitor PCI-32765, Bruton's tyrosine kinase inhibitor PCI-32765, PCI-32765, rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, bendamustine hydrochloride, bendamustin hydrochloride, bendamustine, cytostasan hydrochloride, Treanda, pharmacogenomic studies, Pharmacogenomic Study, pharmacological study, pharmacological studies, laboratory biomarker analysis
Kami Maddocks, MD, Pharmacyclics LLC.
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
03/14
12/24
NCT01829568: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

Active, not recruiting
1
33
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Pharmacological Study, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima
National Cancer Institute (NCI), Celgene Corporation
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma
05/15
01/25
NCT02268851: A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

Checkmark From P1/1b trial in combination with umbralisib in CLL and mantle cell lymphoma at EHA 2020
Jun 2020 - Jun 2020: From P1/1b trial in combination with umbralisib in CLL and mantle cell lymphoma at EHA 2020
Checkmark From a trial for r/r CLL or MCL at EHA 2020
Jun 2020 - Jun 2020: From a trial for r/r CLL or MCL at EHA 2020
Checkmark Results in combination with ibrutinib for CLL & MCL
More
Completed
1
45
US
TGR-1202, RP5264, Umbralisib, Ibrutinib, Imbruvica, CRA-032765, PCI-32765
Dana-Farber Cancer Institute, TG Therapeutics, Inc., The Leukemia and Lymphoma Society, Blood Cancer Research Partnership
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
05/18
08/23
NCT02537613: A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Active, not recruiting
1
54
US
Obinutuzumab, Gazyva, GA-101, Ibrutinib, Imbruvica
Dana-Farber Cancer Institute, Genentech, Inc.
Chronic Lymphocytic Leukemia
03/20
01/29
NCT04115059: Dasatinib In Waldenström Macroglobulinemia

Terminated
1
3
US
Dasatinib, Sprycel
Jorge J. Castillo, MD, Bristol-Myers Squibb
Waldenstrom Macroglobulinemia, DASATINIB
12/21
12/21
NCT02303392: Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Active, not recruiting
1
34
US
Selinexor, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Pharmacological Study, pharmacological studies, Laboratory Biomarker Analysis
Jennifer Woyach, Karyopharm Therapeutics Inc
Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
04/22
12/22
NCT04439006: Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Completed
1
10
US
Best Practice, standard of care, standard therapy, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765
Jennifer Woyach, Janssen Scientific Affairs, LLC
Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Monoclonal B-Cell Lymphocytosis, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
09/22
09/22
NCT03136497: A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Active, not recruiting
1
10
US
ABT-199, A-1195425.0, Venetoclax, Ibrutinib, PIC-32765, Imbruvica, Rituximab, Rituxan
Hackensack Meridian Health, Janssen Scientific Affairs, LLC, Genentech, Inc.
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
12/22
12/22
NCT03225716: A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia

Terminated
1
13
US
Ulocuplumab, BMS-936564, Ibrutinib, Imbruvica
Dana-Farber Cancer Institute, Bristol-Myers Squibb
Waldenstrom's Macroglobulinemia
12/22
12/22
NCT02309580: Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

Completed
1
14
US
Ibrutinib
Memorial Sloan Kettering Cancer Center, Ohio State University, Pharmacyclics LLC., Janssen Biotech, Inc.
T-cell Lymphoma, Relapsed and Refractory T-cell Lymphoma
05/23
05/23
NCT03422393: Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

Active, not recruiting
1
24
US
Venetoclax, Venclexta, Ibrutinib, Imbruvica
Michael Choi, Pharmacyclics LLC.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
08/28
NCT03703167: Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

Active, not recruiting
1
25
US
Ibrutinib, Lenalidomide, Rituximab
Memorial Sloan Kettering Cancer Center, Pharmacyclics LLC.
Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
11/24
11/24
NCT04876092: A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

Active, not recruiting
1
45
Europe
JNJ-67856633, Ibrutinib, JNJ-54179060
Janssen Research & Development, LLC
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin
11/24
11/24
NCT02787369: ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

Active, not recruiting
1
3
US
ACY-1215, Ricolinostat, Ibrutinib, Imbruvica, Idelalisib, Zydelig
Dana-Farber Cancer Institute, Acetylon Pharmaceuticals Incorporated
Recurrent Chronic Lymphoid Leukemia
04/26
04/27
NCT03939182: Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

Active, not recruiting
1
15
US
Abexinostat, Ibrutinib
Memorial Sloan Kettering Cancer Center, Janssen Scientific Affairs, LLC, Xynomic Pharmaceuticals, Inc.
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
05/25
05/25
NCT03400176: VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Terminated
1
39
US
VAY736, ibrutinib, Imbruvica
Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia (CLL)
09/23
09/23
MAPLE-1, NCT04260217: APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia

Recruiting
1
123
US, RoW
APG2575 400 mg, APG2575 600 mg, APG2575 800 mg
Ascentage Pharma Group Inc.
Waldenstrom Macroglobulinemia
12/24
12/25
NCT03702725: Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Active, not recruiting
1
14
US
Ibrutinib, Imbruvica, Lenalidomide, Revlimid, Dexamethasone, Decadron
Alliance Foundation Trials, LLC., Pharmacyclics LLC.
Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma
03/25
03/26
NCT04852692: A Study to Investigate the Comparative Effectiveness of Ibrutinib in Steroid Dependent/Refractory cGVHD Participants

Terminated
N/A
15
RoW
Janssen Korea, Ltd., Korea
Chronic Graft vs Host Disease
08/21
08/21
NCT04016636: A Study to Evaluate Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia

Completed
N/A
50
RoW
Standard of Care
Mela Osorio Maria Jose, Janssen-Cilag Ltd.
CLL
08/21
10/22
NCT05052385: ECP Combination Study

Completed
N/A
319
Europe, RoW
Ruxolitinib, Extracorporeal photopheresis, Ibrutinib
European Society for Blood and Marrow Transplantation, Mallinckrodt
Steroid Refractory GVHD
06/22
06/22
RESIST, NCT05621148: REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy

Completed
N/A
152
Europe
French Innovative Leukemia Organisation, Bristol-Myers Squibb
CLL, Relapsed, CLL, Refractory, Bruton Tyrosine Kinase Inhibitor, Small Lymphocytic Leukemia
12/23
03/24
QOLIBRI, NCT06299540: Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia

Recruiting
N/A
256
Europe
Individual Physical Activity Intervention (IPAI), Ibrutinib
Janssen Cilag S.A.S.
Leukemia, Lymphocytic, Chronic, B-Cell
09/26
12/26
NCT04938141: MEOI and HRQoL in CLL Patients Treated With BTKis

Active, not recruiting
N/A
23
US
AstraZeneca
Chronic Lymphocytic Leukemia
09/24
09/24
NCT05521178: Cardiotoxicities in Patients Receiving BTKi

Withdrawn
N/A
160
NA
Electrocardiogram, ECG, Echocardiogram, TTE, Cardiac magnetic resonance imaging, Cardiac MRI, Mobile cardiac telemetry, Mobile telemetry, Blood pressure monitoring, Home blood pressure monitoring, Blood draw
Dana-Farber Cancer Institute, AstraZeneca
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
01/26
01/28
 

Download Options